Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhCCK
- Development stage
- Preclinical
- Lead developer
- Scintomics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
rhCCK is a preclinical-stage theranostic radiopharmaceutical developed by Scintomics. It is a peptide-based agent designed to target the Cholecystokinin-2 Receptor (CCK2R), which is frequently overexpressed in neuroendocrine-related malignancies such as small cell lung cancer (SCLC) and medullary thyroid cancer (MTC). The "radio-hybrid" (rh) platform allows the peptide to be labeled with various radionuclides: Fluorine-18 (F-18) for positron emission tomography (PET) imaging, or Lutetium-177 (Lu-177) and Actinium-225 (Ac-225) for targeted radionuclide therapy. This approach enables a "see-and-treat" strategy, where the diagnostic version identifies patients with high target expression who are most likely to benefit from the therapeutic version.
- Other names
- rhCCK
02
Targets
CCK2R (Cholecystokinin 2 Receptor)
Beyond the preview
Go deeper on rhCCK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhCCK.